Trials / Unknown
UnknownNCT00568841
Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
A Phase-II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET for Early Prediction of Non-progression in Patients With Advanced NSCLC Treated With Erlotinib and to Associate PET Findings With Molecular Markers
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Lung Cancer Group Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib | erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42) |
| PROCEDURE | FDG-/FLT-PET |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-12-06
- Last updated
- 2009-09-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00568841. Inclusion in this directory is not an endorsement.